These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7165319)

  • 1. Comments on the paper by V. Nitsche et al.: 8-Methoxypsoralen (8-MOP) in neuer galenischer Zubereitung und seine Beziehung zum 8-MOP-Serumspiegel. 8-Methoxypsoralen (8-MOP)--a new galenic form and its relation to 8-MOP serum levels.
    Siddiqui AH
    Arch Dermatol Res; 1982; 272(1-2):181. PubMed ID: 7165319
    [No Abstract]   [Full Text] [Related]  

  • 2. [8-Methoxypsoralen (8-MOP)-a new galenic form and its relation to 8-MOP serum levels (author's transl)].
    Nitsche V; Raff M; Bardach H
    Arch Dermatol Res; 1981; 271(1):11-7. PubMed ID: 7294879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of 8-methoxypsoralen 2 hours after oral administration.
    Steiner I; Prey T; Gschnait F; Washüttl J; Greiter F
    Acta Derm Venereol; 1978; 58(2):185-8. PubMed ID: 76402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Standardizing 8-methoxypsoralen plasma profiles by using an emulsion form.
    Van Boven M; Roelandts R; Adriaens P; Daenens P; Degreef H; Kinget R
    J Am Acad Dermatol; 1985 May; 12(5 Pt 1):822-7. PubMed ID: 4008686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics of 8-methoxypsoralen and 5-methoxypsoralen distribution in guinea pig serum, epidermis and ocular lens.
    Wamer W; Giles A; Kornhauser A
    Photodermatol; 1987 Oct; 4(5):236-9. PubMed ID: 3697346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spectrofluorimetric determination of 5-methoxypsoralen pharmacokinetic in patients' serum.
    Saïd A; Makki S; Muret P; Toubin G; Humbert P; Millet J
    Exp Dermatol; 1997 Apr; 6(2):57-63. PubMed ID: 9209885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between 8-methoxypsoralen skin and blood levels.
    Roelandts R; Van Boven M; Adriaens P; De Schryver F; Degreef H
    J Invest Dermatol; 1983 Oct; 81(4):331-3. PubMed ID: 6619562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum and saliva levels of 8-methoxypsoralen after rectal administration as a micro-enema.
    Stolk L; Siddiqui AH; Kammeyer A; Cormane RH; van Zwieten PA
    Br J Dermatol; 1981 Apr; 104(4):447-51. PubMed ID: 7236508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 8-Methoxypsoralen serum levels in poor responders to photochemotherapy. Importance of drug formulation and individual factors.
    Walther T; Haustein UF
    Int J Dermatol; 1991 Jul; 30(7):516-8. PubMed ID: 1769779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of 5-methoxypsoralen in human serum.
    Wang LH; Tso M
    J Pharm Biomed Anal; 2002 Oct; 30(3):593-600. PubMed ID: 12367684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-response relations in phototoxicity due to 8-methoxypsoralen and UV-A in man.
    Ljunggren B; Bjellerup M; Carter DM
    J Invest Dermatol; 1981 Feb; 76(2):73-5. PubMed ID: 7462679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High plasma levels of 8-methoxypsoralen following bath water delivery in dermatological patients.
    Kappes UP; Barta U; Merkel U; Balogh A; Elsner P
    Skin Pharmacol Appl Skin Physiol; 2003; 16(5):305-12. PubMed ID: 12907835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of bioavailability and phototoxicity of two oral preparations of 5-methoxypsoralen.
    Stolk LM; Siddiqui AH; Westerhof W; Cormane RH
    Br J Dermatol; 1985 Apr; 112(4):469-73. PubMed ID: 3994922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rectal suppositories of 8-methoxsalen produce fewer gastrointestinal side effects than the oral formulation.
    Bolognia JL; Freije L; Amici L; Dellostritto J; Gasparro FP
    J Am Acad Dermatol; 1996 Sep; 35(3 Pt 1):424-7. PubMed ID: 8784281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma levels of 8-methoxypsoralen after bath-PUVA for psoriasis: relationship to disease severity.
    Gómez MI; Azaña JM; Arranz I; Harto A; Ledo A
    Br J Dermatol; 1995 Jul; 133(1):37-40. PubMed ID: 7669638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-Methoxypsoralen (Bergapten) in photochemotherapy of psoriasis.
    Hönigsmann H; Jaschke E; Gschnait F; Brenner W; Fritsch P; Wolff K
    Br J Dermatol; 1979 Oct; 101(4):369-78. PubMed ID: 508604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversible binding of 5- and 8-methoxypsoralen to human serum proteins (albumin) and to epidermis in vitro.
    Artuc M; Stuettgen G; Schalla W; Schaefer H; Gazith J
    Br J Dermatol; 1979 Dec; 101(6):669-77. PubMed ID: 534612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bath-5-methoxypsoralen-UVA therapy for psoriasis.
    Calzavara-Pinton PG; Zane C; Carlino A; De Panfilis G
    J Am Acad Dermatol; 1997 Jun; 36(6 Pt 1):945-9. PubMed ID: 9204060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma levels of 8-methoxypsoralen in psoriatic patients receiving topical 8-methoxypsoralen.
    Neild VS; Scott LV
    Br J Dermatol; 1982 Feb; 106(2):199-203. PubMed ID: 7059510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics of 8-methoxypsoralen following i.v. administration in humans.
    Billard V; Gambus PL; Barr J; Minto CF; Corash L; Tessman JW; Stickney JL; Shafer SL
    Br J Clin Pharmacol; 1995 Oct; 40(4):347-60. PubMed ID: 8554937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.